Cognitive Deficit in AttentionCholTeensNCT05859126
Maternal Choline Supplementation and Offspring Cognition in Adolescence
A study testing Maternal Choline Supplementation 930 mg/d and Maternal Choline Supplementation 480 mg/d in people with Cognitive Deficit in Attention and Executive Dysfunction, run by Cornell University at 1 site in United States.
Trial summary
The goal of this 13-year follow up of a randomized control trial is to study the effect of maternal choline supplementation on offspring cognition in adolescence. The main question[s] it aims to answer are: Does a higher dose of maternal choline choline (930 mg/d day supplementation) lead to improved cognition in… Read more about this study
- Who is it for?
- Ages 13 to 13 yearsHealthy volunteers can take part
- Conditions the study is for
- Cognitive Deficit in Attention, Executive Dysfunction, Emotional Regulation
- What is being tested?
- Maternal Choline Supplementation 930 mg/d and Maternal Choline Supplementation 480 mg/d
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 26 participants
- Where
- 1 siteUnited States
- Study dates
- 23 Jun 2023to Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 13 to 13 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Offspring of mothers from the original choline feeding trial
- Testing will commence when the child reaches 13 years of age (determined by date of birth of participant)
Who cannot join
- Failure to follow the study protocol regarding test procedures and questionnaires
- Lack of internet access with the requisite speed and stability needed to support the online testing tools
Trial locations and contacts
1 site in 1 country.
United States1 site
Cornell University, Division of Nutritional Sciences
Ithaca, New York, 14850
About this study
Official title: The Effect of Maternal Choline Supplementation on Offspring Cognition in Adolescence: A 13 Year Follow-up of a Randomized Feeding Study
The goal of this 13-year follow up of a randomized control trial is to study the effect of maternal choline supplementation on offspring cognition in adolescence.
The main question[s] it aims to answer are:
Does a higher dose of maternal choline choline (930 mg/d day supplementation) lead to improved cognition in adolescence including hippocampal-dependent episodic memory and executive functioning when compared to lower dose supplementation (480 mg/d).
In this follow-up of a clinical trial participants will complete online cognition testing and emotion testing.
Read the detailed description
Eggs are one of the richest dietary sources of choline, an essential nutrient that plays critical roles in fetal development, including shaping the structure and function of the offspring brain. Furthermore, evidence shows that pregnancy dramatically increases the demand for choline.
In rodents consuming standard chow, pregnancy results in a pronounced depletion of maternal choline pools, indicating that choline requirements during pregnancy are increased and that maternal and fetal requirements likely exceed the amount typically consumed by mothers. Additionally, human research from the investigators' laboratory has found that the "Adequate Intake" (AI) levels for choline during pregnancy, set in 1998 and based on the amount needed to prevent liver damage in adult men, may not be sufficient to meet the demands of pregnancy. Specifically, pregnant women consuming choline at the AI level have significantly lower circulating concentrations of several choline metabolites compared to non-pregnant women, and even doubling maternal choline intake (to twice the AI) fails to produce the metabolite levels observed in non-pregnant women. Perhaps most importantly, a substantial body of experimental research in animal models demonstrates that supplementation with additional choline during pregnancy significantly improves lifelong memory, attention, and emotional regulation in offspring, re-duces or eliminates normal ageing-related decline in cognitive function, and reduces the im-pact of a range of prenatal neural insults (e.g., alcohol exposure, maternal stress).
Despite extensive experimental data in animal models demonstrating lasting beneficial effects of maternal choline supplementation on offspring memory, attention, and affect, few studies have evaluated the effects of increasing maternal choline intake in humans. Moreover, results from existing human studies are not sufficiently conclusive to alter dietary intake recommendations for pregnancy. However, a randomized choline feeding trial from the investigators' laboratory demonstrated beneficial effects of increased maternal choline intake (930 mg/d vs. 480 mg/d) on offspring cognitive functioning during infancy and at 7 years of age (work supported in part by previous ENC funding). Based on these findings, the investigators propose to follow up children born to mothers participating in this trial, to examine longer-term effects of maternal choline supple-mentation on child cognition and emotional well-being at thirteen years of age. This will be the first randomized controlled trial (RCT) following children into adolescence, a time when tests are highly predictive of adult functioning.
Choline is an essential nutrient that plays critical roles in fetal neurodevelopment. The demand for choline increases markedly during pregnancy, indicated by a pronounced depletion of maternal choline pools even when women consume the Adequate Intake (AI) level. It is a concern that fewer than 10% of reproductive age women achieve the recommended AI level, and that choline is not included in standard prenatal vitamin regimens.
Decades of rodent studies show that maternal choline intake affects offspring brain structure, neural function and cognitive performance throughout life the lifespan. Maternal choline deficiency produces lasting offspring cognitive impairment, whereas increasing maternal choline intake markedly improves offspring cognition and provides widespread neuroprotection in various diseases and early insults.
Only 3 Randomized Controlled Trials (RCTs) have evaluated offspring cognition following maternal choline supplementation (MCS) in healthy human pregnancies. One trial conducted in the investigators' lab demonstrated that MCS improves offspring cognition during infancy and early childhood, but no studies have yet determined whether the beneficial effects observed in the immature human brain are maintained in adulthood. This question can be addressed by assessing the cognitive performance of MCS offspring in adolescence, a time when many neurocognitive tests are strong predictors of ultimate adult functioning.
The planned study will take advantage of the unique opportunity to follow up the offspring of women who participated in a controlled feeding study comparing two levels of choline intake during pregnancy: 480 vs 930 mg/d. The offspring will be tested at 13 years old, an age when cognitive functioning predicts adult functioning. The investigators predict that the cognitive performance of the children born to women consuming 480 mg/d (approximately the AI) during the last trimester of pregnancy will be poorer than children born to women consuming 930 mg/d.
The predicted results would strongly indicate that the low choline intake of most pregnant women impedes the lifelong cognitive functioning of their children. Demonstrating this effect would spur the addition of choline to standard prenatal vitamin regimens-the predicted result being population-wide improvements in cognitive functioning, in part due to widespread neuroprotection. These effects would be particularly beneficial for at-risk pregnancies and underserved populations.
- Being tested
- Maternal Choline Supplementation 930 mg/d, Maternal Choline Supplementation 480 mg/d
- Keywords
- adolescence, emotion, cognition, choline
- Medical subject headings
- Emotional Regulation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Maternal Choline Supplementation 930 mg/dDietary supplement
Mothers were supplemented with choline (930mg/d) from second trimester through birth. This is a 13 year follow up of their offspring.
Maternal Choline Supplementation 480 mg/dDietary supplement
Mothers were supplemented with choline (480 mg/d) from second trimester through birth. This is a 13 year follow up of their offspring.
| Study group | Role | What they receive |
|---|---|---|
| Maternal Choline Supplementation 930 mg/d | Experimental | Supplementation of 930 mg/d from early second trimester through birth. Offspring are followed for cognitive outcomes. Receives: Dietary Supplement: Maternal Choline Supplementation 930 mg/d |
| Maternal Choline Supplementation 480mg/d | Active comparator | Supplementation of 480 mg/d from early second trimester through birth.Offspring are followed for cognitive outcomes. Receives: Dietary Supplement: Maternal Choline Supplementation 480 mg/d |
What is being measured
The primary outcome is the main question the study is designed to answer.
CANTAB Signal Detection test
To measure selective and sustained attention where sensitivity to stimulus ranges from 0 (bad) to 1 (good)
Measured: at 13 years of age
CANTAB Delayed Matching to Sample
To measure memory where scoring is based on percent correct where 0% is bad and 100% is excellent), Paired Associates Learning (where scoring is based on total errors, where 0 is best), and Pattern Recognition Memory (where outcome is measured as percentage of correct trials and latency (speed of participant's response).)
Measured: at 13 years of age
CANTAB Spatial Working Memory
To measure executive function (where outcome measure is number of errors and lower is better),
Measured: at 13 years of age
CANTAB Cambridge Gambling
To measure executive function (where outcome measure is number of errors and lower is better),
Measured: at 13 years of age
Secondary outcomes (2)
Child Behavior Checklist (CBCL)
To measure emotion regulation where scoring is from 0-226 and lower is better.
Measured: at 13 years of age
Youth Self Report (CBCL
To measure emotion regulation where scoring is from 0-226 and lower is better.
Measured: at 13 years of age
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2023
- Study start23 Jun 2023
- Primary completionOct 2024 (estimated)
- Study completionDec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cognitive Deficit in AttentionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 26 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cornell University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Barbara Strupp, PhD, Principal investigator, Cornell University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05859126
- Sponsor's protocol ID
- IRB0147236
- Acronym
- CholTeens
- Status last verified
- Aug 2024
- First submitted
- 30 Mar 2023
- Last updated
- 22 Aug 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Roth SA, Lam AE, Strupp BJ, Canfield RL, Larson EA. The Effect of Maternal Choline Intake on Offspring Cognition in Adolescence: Protocol for a 14-year Follow-Up of a Randomized Controlled Feeding Trial. JMIR Res Protoc. 2025 Jul 11;14:e73508. doi: 10.2196/73508.
PubMed 40644695
Study at a glance
From the registry record, last updated by the sponsor on 22 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Maternal Choline Supplementation on Offspring Cognition in Adolescence: A 13 Year Follow-up of a Randomized Feeding Study
- ClinicalTrials.gov ID
- NCT05859126
- Acronym / sponsor ID
- CholTeens / IRB0147236
- Keywords
- adolescence, emotion, cognition, choline
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 26 participants (estimated)
- Lead sponsor
- Cornell UniversityUniversity, hospital or other
- Study start
- 23 Jun 2023 (actual)
- Primary completion
- Oct 2024 (estimated)
- Study completion
- Dec 2024 (estimated)
- First posted
- 15 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this 13-year follow up of a randomized control trial is to study the effect of maternal choline supplementation on offspring cognition in adolescence.
The main question[s] it aims to answer are:
Does a higher dose of maternal choline choline (930 mg/d day supplementation) lead to improved cognition in adolescence including hippocampal-dependent episodic memory and executive functioning when compared to lower dose supplementation (480 mg/d).
In this follow-up of a clinical trial participants will complete online cognition testing and emotion testing.
Detailed description
Eggs are one of the richest dietary sources of choline, an essential nutrient that plays critical roles in fetal development, including shaping the structure and function of the offspring brain. Furthermore, evidence shows that pregnancy dramatically increases the demand for choline.
In rodents consuming standard chow, pregnancy results in a pronounced depletion of maternal choline pools, indicating that choline requirements during pregnancy are increased and that maternal and fetal requirements likely exceed the amount typically consumed by mothers. Additionally, human research from the investigators' laboratory has found that the "Adequate Intake" (AI) levels for choline during pregnancy, set in 1998 and based on the amount needed to prevent liver damage in adult men, may not be sufficient to meet the demands of pregnancy. Specifically, pregnant women consuming choline at the AI level have significantly lower circulating concentrations of several choline metabolites compared to non-pregnant women, and even doubling maternal choline intake (to twice the AI) fails to produce the metabolite levels observed in non-pregnant women. Perhaps most importantly, a substantial body of experimental research in animal models demonstrates that supplementation with additional choline during pregnancy significantly improves lifelong memory, attention, and emotional regulation in offspring, re-duces or eliminates normal ageing-related decline in cognitive function, and reduces the im-pact of a range of prenatal neural insults (e.g., alcohol exposure, maternal stress).
Despite extensive experimental data in animal models demonstrating lasting beneficial effects of maternal choline supplementation on offspring memory, attention, and affect, few studies have evaluated the effects of increasing maternal choline intake in humans. Moreover, results from existing human studies are not sufficiently conclusive to alter dietary intake recommendations for pregnancy. However, a randomized choline feeding trial from the investigators' laboratory demonstrated beneficial effects of increased maternal choline intake (930 mg/d vs. 480 mg/d) on offspring cognitive functioning during infancy and at 7 years of age (work supported in part by previous ENC funding). Based on these findings, the investigators propose to follow up children born to mothers participating in this trial, to examine longer-term effects of maternal choline supple-mentation on child cognition and emotional well-being at thirteen years of age. This will be the first randomized controlled trial (RCT) following children into adolescence, a time when tests are highly predictive of adult functioning.
Choline is an essential nutrient that plays critical roles in fetal neurodevelopment. The demand for choline increases markedly during pregnancy, indicated by a pronounced depletion of maternal choline pools even when women consume the Adequate Intake (AI) level. It is a concern that fewer than 10% of reproductive age women achieve the recommended AI level, and that choline is not included in standard prenatal vitamin regimens.
Decades of rodent studies show that maternal choline intake affects offspring brain structure, neural function and cognitive performance throughout life the lifespan. Maternal choline deficiency produces lasting offspring cognitive impairment, whereas increasing maternal choline intake markedly improves offspring cognition and provides widespread neuroprotection in various diseases and early insults.
Only 3 Randomized Controlled Trials (RCTs) have evaluated offspring cognition following maternal choline supplementation (MCS) in healthy human pregnancies. One trial conducted in the investigators' lab demonstrated that MCS improves offspring cognition during infancy and early childhood, but no studies have yet determined whether the beneficial effects observed in the immature human brain are maintained in adulthood. This question can be addressed by assessing the cognitive performance of MCS offspring in adolescence, a time when many neurocognitive tests are strong predictors of ultimate adult functioning.
The planned study will take advantage of the unique opportunity to follow up the offspring of women who participated in a controlled feeding study comparing two levels of choline intake during pregnancy: 480 vs 930 mg/d. The offspring will be tested at 13 years old, an age when cognitive functioning predicts adult functioning. The investigators predict that the cognitive performance of the children born to women consuming 480 mg/d (approximately the AI) during the last trimester of pregnancy will be poorer than children born to women consuming 930 mg/d.
The predicted results would strongly indicate that the low choline intake of most pregnant women impedes the lifelong cognitive functioning of their children. Demonstrating this effect would spur the addition of choline to standard prenatal vitamin regimens-the predicted result being population-wide improvements in cognitive functioning, in part due to widespread neuroprotection. These effects would be particularly beneficial for at-risk pregnancies and underserved populations.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Maternal Choline Supplementation 930 mg/d | Experimental | Dietary Supplement: Maternal Choline Supplementation 930 mg/dSupplementation of 930 mg/d from early second trimester through birth. Offspring are followed for cognitive outcomes. |
| Maternal Choline Supplementation 480mg/d | Active comparator | Dietary Supplement: Maternal Choline Supplementation 480 mg/dSupplementation of 480 mg/d from early second trimester through birth.Offspring are followed for cognitive outcomes. |
Who may qualify
- Ages
- 13 to 13 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (2 listed)
- Offspring of mothers from the original choline feeding trial
- Testing will commence when the child reaches 13 years of age (determined by date of birth of participant)
Key exclusion criteria (2 listed)
- Failure to follow the study protocol regarding test procedures and questionnaires
- Lack of internet access with the requisite speed and stability needed to support the online testing tools
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Maternal Choline Supplementation 930 mg/dMothers were supplemented with choline (930mg/d) from second trimester through birth. This is a 13 year follow up of their offspring. | Dietary supplement | Maternal Choline Supplementation 930 mg/d |
| Maternal Choline Supplementation 480 mg/dMothers were supplemented with choline (480 mg/d) from second trimester through birth. This is a 13 year follow up of their offspring. | Dietary supplement | Maternal Choline Supplementation 480mg/d |
Primary outcome
CANTAB Signal Detection test
Time frame: at 13 years of age
To measure selective and sustained attention where sensitivity to stimulus ranges from 0 (bad) to 1 (good)
CANTAB Delayed Matching to Sample
Time frame: at 13 years of age
To measure memory where scoring is based on percent correct where 0% is bad and 100% is excellent), Paired Associates Learning (where scoring is based on total errors, where 0 is best), and Pattern Recognition Memory (where outcome is measured as percentage of correct trials and latency (speed of participant's response).)
CANTAB Spatial Working Memory
Time frame: at 13 years of age
To measure executive function (where outcome measure is number of errors and lower is better),
CANTAB Cambridge Gambling
Time frame: at 13 years of age
To measure executive function (where outcome measure is number of errors and lower is better),
2 secondary outcomes
Child Behavior Checklist (CBCL)
Time frame: at 13 years of age
Youth Self Report (CBCL
Time frame: at 13 years of age
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Aug 2024.
- Derived from this study: PubMed 40644695Roth SA, Lam AE, Strupp BJ, Canfield RL, Larson EA. The Effect of Maternal Choline Intake on Offspring Cognition in Adolescence: Protocol for a 14-year Follow-Up of a Randomized Controlled Feeding Trial. JMIR Res Protoc. 2025 Jul 11;14:e73508. doi: 10.2196/73508.
- Individual participant dataSharing planned: No
Related trials for Cognitive Deficit in Attention
RecruitingObservational study
Psychotherapy for Irritability in Youth: Comparing Active Treatment to Nonactive Psychoeducation Supportive Psychotherapy
Irritability, Disruptive Mood Dysregulation Disorder
Not yet recruiting
Cognitive-Motor Training With the DextEgg in Children With ADHD
Attention Deficit Hyperactivity Disorder (ADHD)
Active, not recruitingObservational study
A Study of Attention and Memory Processes in Breast Cancer Survivors
Breast Cancer Survivors
Recruiting
Strengthening Neuro-Cognitive Skills for Success in School, Work and Beyond
TBI, Cognitive Dysfunction
RecruitingObservational study
Post Operative Cognitive Dysfunction After Oncologic Surgery
Emergence Delirium, Post-Operative Cognitive Dysfunction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Barbara Strupp, PhD principal investigator
Cornell University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Maternal Choline Supplementation 930 mg/d and Maternal Choline Supplementation 480 mg/d in people with Cognitive Deficit in Attention and Executive Dysfunction, run by Cornell University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 22 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
CANTAB Signal Detection test (time frame: at 13 years of age). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05859126, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Aug 2024.